Central administration of insulin-like growth factor-I (IGF-I) attenuates sickness behavior in response to the cytokine inducer lipopolysaccharide. The present study was designed to determine the respective roles of the two main proinXammatory cytokines, tumor necrosis factor (TNF ) and interleukin-1 (IL-1 ), in these eVects. Male CD1 mice were injected into the lateral ventricle (i.c.v.) of the brain with optimal amounts of either TNF (50 ng) or IL-1 (2 ng) that induce sickness behavior. Behavioral responses to IGF-I (0, .1, and 1 g) also given i.c.v. were measured at various time intervals before and after treatment with the two proinXammatory cytokines. Mice treated with TNF and IL-1 lost body weight and displayed equivalent reductions in social exploration and instances of immobility. At the dose of .1 g, IGF-I attenuated these signs of sickness in TNF -but not in IL-1 -treated mice. At the dose of 1 g, IGF-I attenuated IL-1 -induced immobility and the reduction in social exploration but had no eVect on loss of body weight. These Wndings indicate that IGF-I is more potent in attenuating sickness behavior induced by TNF than that caused by IL-1 , which is consistent with the relative speciWcity of the TNF /IGF-I interactions in the brain. 
Introduction
Insulin-like growth factor-I (IGF-I) is a multifunctional peptide that is essential for normal growth and development. Its actions are mediated primarily by the IGF-I receptor which is a transmembrane, ligand-activated tyrosine protein kinase highly homologous to the insulin receptor. Multiple signaling pathways are activated by the IGF-I receptor, including the mitogen-activated protein kinase and phosphatidylinositol 3Ј kinase signaling pathways (Dupont et al., 2003; Vincent and Feldman, 2002) . IGF-I promotes cell proliferation and inhibits cell death during both normal development and during stress and disease. These actions also occur in the central nervous system. Transgenic mice overexpressing IGF-I postnatally exhibit brain overgrowth characterized by increased neuron and oligodendrocyte number, as well as marked increases in myelination (D'Ercole et al., 2002) . Mutant mice with ablated IGF-I and IGF-I receptor expression, as well as those with overexpression of the binding proteins to IGF-I that are capable of inhibiting IGF-I actions, exhibit brain growth retardation, decreases in glucose utilization (Cheng et al., 2000) and disruption in lipid and microtubule metabolism, leading to impaired neuronal somatic and dendritic growth (Cheng et al., 2003) . These studies conWrm a role for IGF-I in neural development, and indicate that IGF-I stimulates neurogenesis and synaptogenesis, facilitates oligodendrocyte development, promotes neuron and oligodendrocyte survival, and stimulates myelination.
